Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) closed the day trading at $0.73 up 12.14% from the previous closing price of $0.65. In other words, the price has increased by $+0.0790 from its previous closing price. On the day, 1037099 shares were traded.
Ratios:
For a better understanding of BCLI, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.24 and its Current Ratio is at 0.24.
Maxim Group reiterated its Buy rating for the stock on December 19, 2016, while the target price for the stock was revised from $5 to $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 01 ’23 when Lindborg Stacy bought 11,500 shares for $1.77 per share. The transaction valued at 20,402 led to the insider holds 181,500 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCLI now has a Market Capitalization of 49.38M and an Enterprise Value of 49.36M.
Stock Price History:
Over the past 52 weeks, BCLI has reached a high of $3.37, while it has fallen to a 52-week low of $0.13. The 50-Day Moving Average of the stock is 0.4272, while the 200-Day Moving Average is calculated to be 0.7424.
Shares Statistics:
Over the past 3-months, BCLI traded about 955.69K shares per day on average, while over the past 10 days, BCLI traded about 1.5M shares per day. A total of 60.49M shares are outstanding, with a floating share count of 56.13M. Insiders hold about 17.86% of the company’s shares, while institutions hold 5.80% stake in the company. Shares short for BCLI as of Mar 15, 2024 were 850.26k with a Short Ratio of 0.89, compared to 1.23M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.74% and a Short% of Float of 1.82%.
Earnings Estimates
Current recommendations for the stock of the company come from 0 analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.19. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.7 and -$0.7 for the fiscal current year, implying an average EPS of -$0.7. EPS for the following year is -$0.47, with 1 analysts recommending between -$0.47 and -$0.47.
